Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 1993;13:1755-1762

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Contacos, C.
Right arrow Articles by Sullivan, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Contacos, C.
Right arrow Articles by Sullivan, D. R.

Arteriosclerosis and Thrombosis, Vol 13, 1755-1762, Copyright © 1993 by American Heart Association

ARTICLES

Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia

C Contacos, PJ Barter and DR Sullivan
Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

This study compared the effects of a 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitor, fish oil, and placebo on plasma lipids and lipoproteins in patients with mixed hyperlipidemia. After an initial run-in phase, 32 patients were randomized for 6 weeks to either (1) pravastatin 40 mg/d, n = 10; (2) fish oil (himega 6 g/d, equivalent to 3 g omega-3 fatty acids/d), n = 10; or (3) placebo. After single drug therapy, in the pravastatin group mean total plasma cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein (apo) B fell significantly by 23% (P < .001), 30% (p < .001), and 26% (P < .01), respectively. LDL Stokes' diameter did not change. In the fish oil group mean plasma triglycerides (TG) fell 30% (P < .05), LDL Stokes' diameter increased from 25.0 to 25.9 nm (P < .05), and there was a nonsignificant increase in LDL-C. There were no changes in the placebo group. To assess the effect of the combination of pravastatin plus fish oil therapy, all patients, except one woman from the placebo group who developed nausea on fish oil, then took combined therapy of pravastatin 40 mg/d plus fish oil 6 g/d for an additional 12 weeks. In each case, there were no clinically significant episodes of muscle tenderness or elevation of creatine phosphokinase or alanine aminotransferase. After 12 weeks of combined therapy of pravastatin plus fish oil, there were significant reductions in the mean TC, TG, LDL-C, and apoB in the three groups compared with baseline levels.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel
The Metabolic Syndrome
Endocr. Rev., December 1, 2008; 29(7): 777 - 822.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
L. K Nies, A. A Cymbala, S. L Kasten, D. G Lamprecht, and K. L Olson
Complementary and Alternative Therapies for the Management of Dyslipidemia
Ann. Pharmacother., November 1, 2006; 40(11): 1984 - 1992.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
M. Rizzo and K. Berneis
Low-density lipoprotein size and cardiovascular risk assessment
QJM, January 1, 2006; 99(1): 1 - 14.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
D. Bhatnagar, M.I. Mackness, and P.N. Durrington
Treatment of mixed hyperlipidaemia using a combination of omega-3 fatty acids and HMG CoA reductase inhibitor
Eur. Heart J. Suppl., June 1, 2001; 3(suppl_D): D53 - D58.
[Abstract] [PDF]

Home page
 HeartHome page
P N Durrington, D Bhatnagar, M I Mackness, J Morgan, K Julier, M A Khan, and M France
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia
Heart, May 1, 2001; 85(5): 544 - 548.
[Abstract] [Full Text]

Home page
 CirculationHome page
W. Marz, H. Scharnagl, C. Abletshauser, M. M. Hoffmann, A. Berg, J. Keul, H. Wieland, and M. W. Baumstark
Fluvastatin Lowers Atherogenic Dense Low-Density Lipoproteins in Postmenopausal Women With the Atherogenic Lipoprotein Phenotype
Circulation, April 17, 2001; 103(15): 1942 - 1948.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
K. D Stark, E. J Park, V. A Maines, and B. J Holub
Effect of a fish-oil concentrate on serum lipids in postmenopausal women receiving and not receiving hormone replacement therapy in a placebo-controlled, double-blind trial
Am. J. Clinical Nutrition, August 1, 2000; 72(2): 389 - 394.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. M. Minihane, S. Khan, E. C. Leigh-Firbank, P. Talmud, J. W. Wright, M. C. Murphy, B. A. Griffin, and C. M. Williams
ApoE Polymorphism and Fish Oil Supplementation in Subjects With an Atherogenic Lipoprotein Phenotype
Arterioscler Thromb Vasc Biol, August 1, 2000; 20(8): 1990 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
T. A Mori, V. Burke, I. B Puddey, G. F Watts, D. N O'Neal, J. D Best, and L. J Beilin
Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men
Am. J. Clinical Nutrition, May 1, 2000; 71(5): 1085 - 1094.
[Abstract] [Full Text] [PDF]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1993 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.